Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK) : a French nationwide cohort retrospective study

  • Etude concernée: IFCT-1302
  • Auteurs / Authors: Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D
  • Journal / Conference: Oncotarget
  • Année / Year: 2017
  • PMID: 28423535
  • Lien vers la publication: https://www.ncbi.nlm.nih.gov/pubmed/28423535
  • PDF: Overall_survival_with_crizotinib_Oncotarget.pdf